Lilly’s High, Viking’s Gamble: 2026 Vision

But here’s the thing about frenzies: they don’t last. Someone always crashes the party. And that’s where Viking Therapeutics comes in. A biotech, still wet behind the ears, but with a potential weapon in its arsenal: VK2735. Injectable and oral? Now you’re talking. A dual GIP/GLP-1 receptor agonist? Sounds like something out of a science fiction novel, but the results are… promising. Fourteen-point-seven percent weight loss in thirteen weeks? Without a plateau? That’s not incremental improvement, that’s a goddamn landslide. They’re playing with fire, and I, for one, am watching with a morbid fascination.








